Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Primary bronchi

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10 result(s) found for: Primary bronchi. Displaying page 1 of 1.
    EudraCT Number: 2013-000370-30 Sponsor Protocol Number: 20150706 Start Date*: 2015-11-26
    Sponsor Name:Norrlands University Hospital
    Full Title: Diagnosis and follow up of neuroendocrine tumours with 68Ga-DotaToc PET/CT
    Medical condition: Neuroendocrine tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005293-22 Sponsor Protocol Number: D589GC00003 Start Date*: 2014-08-06
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 3, 12-Week, Double-Blind, Randomized, Parallel-Group, Multicenter Study Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 ug, 2 Actuations Twice Daily, and Symbicort pMDI 80...
    Medical condition: Asthma
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2006-006624-19 Sponsor Protocol Number: AVF3671g Start Date*: 2007-11-19
    Sponsor Name:Genentech, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE IIIb TRIAL COMPARING BEVACIZUMAB THERAPY WITH OR WITHOUT ERLOTINIB AFTER COMPLETION OF CHEMOTHERAPY WITH BEVACIZUMAB FOR THE FIRST-LINE TREATM...
    Medical condition: Non-small-cell-lung-cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066490 Progression of non small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) BG (Prematurely Ended) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006626-26 Sponsor Protocol Number: OSI3364g Start Date*: 2007-07-18
    Sponsor Name:Genentech, Inc.
    Full Title: A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination with Tarceva (erlotinib) Compared With Tarceva Alone For...
    Medical condition: Non-small-cell-lung-cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066490 Progression of non small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) BG (Prematurely Ended) SE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018316-32 Sponsor Protocol Number: D589GC00002 Start Date*: 2010-11-23
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2, randomized, blinded, 5-period cross-over, placebo and activecontrolled, multicenter, dose-finding study of single doses of formoterol 2.25 μg, 4.5 μg, and 9 μg delivered via Symbicort pM...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003553 Asthma LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-018315-15 Sponsor Protocol Number: D589GC00001 Start Date*: 2010-06-09
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2, double-blind, randomized, parallel-group, placebo-controlled, multicenter study, comparing budesonide pMDI 160 μg bid with placebo, a 6-week efficacy and safety study in children aged 6 ...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003553 Asthma LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) LV (Completed) HU (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-008731-28 Sponsor Protocol Number: DPM-B-305 Start Date*: 2009-06-05
    Sponsor Name:Pharmaxis Pharmaceuticals Limited
    Full Title: A phase III multicentre, randomized, parallel, controlled, double blind study to investigate the safety and efficacy of inhaled mannitol over 12 months in the treatment of bronchiectasis.
    Medical condition: Bronchiectasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003331-32 Sponsor Protocol Number: AZI003 Start Date*: 2013-06-18
    Sponsor Name:KULeuven and University Hospitals Leuven
    Full Title: A PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF PRE-TRANSPLANT AND PROMPT POST-TRANSPLANT TREATMENT WITH AZITHROMYCIN TO IMPROVE EARLY ALLOGRAFT FUNCTION AND OUTCOME AFTER LUNG TRANSPLANTA...
    Medical condition: EARLY LUNG ALLOGRAFT FUNCTION AND OUTCOME AFTER LUNG TRANSPLANTATION
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10050437 Prophylaxis against heart and lung transplant rejection LLT
    14.1 10022891 - Investigations 10016547 FEV LLT
    14.1 10042613 - Surgical and medical procedures 10050433 Prophylaxis against lung transplant rejection LLT
    14.1 10022891 - Investigations 10006414 Bronchial biopsy abnormal LLT
    14.1 10022891 - Investigations 10025041 Lung biopsy abnormal LLT
    14.1 10022891 - Investigations 10016549 FEV 1 abnormal LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10049202 Bronchiolitis obliterans LLT
    14.1 10042613 - Surgical and medical procedures 10025127 Lung transplant PT
    14.1 10021428 - Immune system disorders 10049237 Acute cellular rejection LLT
    14.1 10021428 - Immune system disorders 10066543 Acute allograft rejection LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039008 Reversible airways obstruction NOS LLT
    14.1 10021428 - Immune system disorders 10019319 Heart-lung transplant rejection PT
    14.1 10022891 - Investigations 10016550 FEV 1 decreased LLT
    14.1 10022891 - Investigations 10057799 Computerised tomogram thorax abnormal PT
    14.1 10022891 - Investigations 10063078 Bronchoalveolar lavage abnormal PT
    14.1 10042613 - Surgical and medical procedures 10056409 Heart and lung transplant PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10068956 Respiratory tract inflammation PT
    14.1 100000004862 10049083 Respiratory tract infection NOS LLT
    14.1 10022891 - Investigations 10016553 FEV 1 low LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005264-86 Sponsor Protocol Number: 1182.98 Start Date*: 2007-02-21
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: Safety, efficacy and Pharmacokinetics of tipRanavir boosted with low-dose ritonavir (TPV/r) 500 mg/200 mg BID IN a racially and Gender diverse HIV positive treatment experienced population with a p...
    Medical condition: The objective of this study is to demonstrate the safety and efficacy of TPV/r among a racially diverse HIV-positive population of females and males who are three-class (NRTI, NNRTI, and PI) experi...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005023-33 Sponsor Protocol Number: 1182.99 Start Date*: 2007-03-15
    Sponsor Name:Boehringer Ingelheim France SAS
    Full Title: Safety and efficacy study of TPV boosted with low dose ritonavir (TPV/r) 500 mg/200 mg BID in antiretroviral treatment experienced HIV positive patients with HCV or HBV co-infection, with a pilot e...
    Medical condition: Treatment with three-class (NRTI, NNRTI, and PI) experienced HIV positive patients with HCV or HBV co-infection, with a minimum of 3-months duration for each class and have documented resistance to...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020192 HIV-1 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) PT (Prematurely Ended) ES (Completed) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 08:02:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA